Buy Full Version
"Europe IVD Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Europe IVD Market by Product Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Blood Testing, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Other Indications), and by End Users (Standalone Laboratory, Hospitals, Academic and Medical Schools, Point of Care Testing, and Others) - Opportunity Analysis and Industry Forecast, 2017-2023
Update Available On-Demand

Diagnostics and Biotech	LI_174352	Pages: 180	Sep 2017 \| 4466 Views
Author(s) : Abha Thakur	Tables: 69	Charts: 54	Formats*:

Europe IVD Market Overview:

The Europe IVD Market is accounted for $19,124 million in 2016, and is estimated to reach $26,623 million by 2023, growing at a CAGR of 4.7% during the analysis period (20172022). IVD diagnostics involve non-invasive tests performed on biological samples such as, blood, urine, and tissues to detect the diseases. These tests are used for diagnosis, screening, and therapeutic monitoring of diseases. In addition, IVD tests is performed in laboratories, hospitals, and special tests such as, pregnancy tests and glucose monitoring that are performed at home.

Rise in incidence & prevalence of chronic disease, technological advancements in IVD technique, and rise in healthcare expenditure fuel the market growth during the analysis period. However, shortage of experienced healthcare professionals and lack of awareness among the population restrict the growth of the market.

Market Segmentation

Get more information on this report : Request Sample Pages

Segment Review

Based on product type, the market is categorized into reagents, instruments, and software & services. The reagent segment accounted for the highest market share in 2016, and the software & services is expected to grow at the highest growth rate during the forecast period. The growth of the reagent market is attributed to the recent introduction of new novel reagents and wide availability of effective and cost-efficient reagents. On the basis of techniques, the immunodiagnostics segment captured the highest market share in 2016, owing to the increase in demand for personalized medicines. On the basis of application, infectious diseases segment captured the highest market share in 2016, owing to the increase in prevalence of infectious diseases and rise in preventive healthcare awareness among the population. Based on end users, the standalone laboratory segment captured the highest market share in 2016, primarily due to non-availability of complex tests in hospitals and commercial clinics.

Top Investment Pocket

Get more information on this report : Request Sample Pages

Country Wise Review

Country wise, it is analyzed across the UK, Germany, France, Italy, Spain, and Rest of Europe. Germany accounted for the highest share of the market in 2016, followed by China. France is anticipated to witness the highest growth rate during the forecast period. Increase in prevalence of chronic and infectious diseases and rise in government investments for R&D and the healthcare drive the market growth. France is expected to emerge as the area with maximum growth potential due to focus of key players in the emerging economies and improvement in healthcare infrastructure.

Europe IVD Market ($Million), 2017-2023

Get more information on this report : Request Sample Pages

Increase in Prevalence of Chronic Diseases

IVD market in the European countries is in trend due to increase in incidences of chronic diseases such as cancer, cardiovascular diseases, neurodegenerative disorder, and diabetes. Chronic disease is a leading cause of death in Europe, for instance, the incidence of chronic diseases is high in high-income countries. According to WHO, incidence, prevalence, severity and duration, and mortality for more than 130 major causes, which includes data since 2000 for WHO member countries and for sub-regions throughout the world (WHO 2008a, WHO 2008b; WHO 2009). Thus, high share of chronic diseases compared with communicable, maternal, perinatal and nutritional conditions, as well as injuries in low income, lower middle income, upper middle income, and high-income countries.

Rise in Geriatric Population

The Europe IVD market is on an increase owing to rise in geriatric population as there is a rise in the number in volume of chronic diseases. For instance, the population of the EU-28 on January 1, 2016 was estimated at 510.3 million. Young people (0 to 14 years old) made up 15.6 % of the EU-28s population, while people considered to be of working age (15 to 64 years old) accounted for 65.3 % of the population. Older people (aged 65 or over) had a 19.2 % share (an increase of 0.3 % compared with the previous year and an increase of 2.4 % compared with 10 years earlier), which estimated that European countries accounted for highest aging population and size of aging population continues to lead during the forecast period.

Technological Advancement in IVD

In the past 50 years, IVD technologies were used only in clinical labs. Initially, pregnancy test was undertaken in laboratories; however, these days the tests are conducted at home by placing urine samples on test sticks. These offer accurate results, are less time consuming, and can be easily performed. Similarly, the blood glucose levels testing can be done using point-of-care testing devices such as glucometer. Similarly, the HIV test can also be conducted at home using a mouth swab that is inbuilt in the diagnosis device. It provides results in 2040 minutes. Previously, these tests were carried out in clinical laboratories where individual blood sample was taken.

Major companies operating in the market adopt product launch as their key development strategy. Companies profiled in this market include Thermo Fisher Scientific Inc., Alere Inc., Biomerieux, Danaher Corporation, F. Hoffmann-La Roche AG, Becton Dickinson and Company, Bio-Rad Laboratories, Bayer AG, Sysmex Corporation, and Johnson & Johnson.

Key Benefits:

The study provides an in-depth analysis of the Europe IVD market with current trends and future estimations to elucidate the imminent investment pockets
The report provides a quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on prevailing market opportunities
Extensive analysis by technology and application helps understand various trends and prevailing opportunities in the respective market
Comprehensive analysis of all countries is provided, which determines the main opportunities in these geographies
Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which predict the competitive outlook of the Europe IVD market

Europe IVD Market Key Segments:

By Product Type

Reagents
Instruments
Software and Services

By Techniques

Immunodiagnostics
- Enzyme-Linked Immunosorbent Assay (ELISA)
  - Chemiluminescence Immunoassays (CLIAS)
  - Fluorescence Immunoassays (FIAS)
  - Colorimetric Immunoassays (CIS)
- Rapid Tests
- Enzyme-Linked Immunospot Assays (ELISPOT)
- Radioimmunoassay
- Western Blot
Blood Testing
Molecular Diagnostics
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Hybridization
- DNA Diagnostics
- Microarrays
- Others
Tissue Diagnostics
Clinical Chemistry
- Basic Metabolic Panel
- Liver Panel
- Lipid Profile
- Thyroid Function Panel
- Renal Profile
- Electrolyte Panel
- Specialty Chemicals
Other IVD Techniques

By Application

Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Other Indications

By End Users

Standalone Laboratory
Hospitals
Academic and Medical Schools
Point of Care Testing
Others

By Country

UK
Germany
France
Spain
Italy
Rest of Europe

CHAPTER 1 INTRODUCTION

1.1 REPORT DESCRIPTION
1.2 KEY BENEFITS
1.3 KEY MARKET SEGMENTS
1.4 RESEARCH METHODOLOGY

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 PORTER’S FIVE FORCES ANALYSIS

3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry

3.4 MARKET SHARE ANALYSIS, 2016
3.5 MARKET DYNAMICS

3.5.1 Drivers

3.5.1.1 Increasing incidence of chronic and infectious diseases
3.5.1.2 Technological advancements in IVD
3.5.1.3 Emergence of minimal invasive technologies
3.5.1.4 Increasing government expenditures on healthcare
3.5.1.5 Increase in popularity of personalized medicine approach

3.5.2 Restraint

3.5.2.1 Unclear reimbursement policies
3.5.2.2 Stringent regulatory policies

3.5.3 Opportunity

3.5.3.1 Potential opportunities for outsourcing
3.5.3.2 Convergence of new technologies

CHAPTER 4 IVD MARKET, BY PRODUCT TYPE

4.1 OVERVIEW

4.1.1 Market size and forecast

4.2 REAGENTS

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 INSTRUMENTS

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 SOFTWARE AND SERVICES

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

CHAPTER 5 IVD MARKET, BY TECHNIQUE

5.1 OVERVIEW

5.1.1 Market size and forecast

5.2 IMMUNODIAGNOSTICS

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 Enzyme-linked immunosorbent assay (ELISA)

5.2.4.1 Market size and forecast
5.2.4.2 Chemiluminescence immunoassay (CLIA)

5.2.4.2.1 Market size and forecast

5.2.4.3 Fluorescence immunoassay (FIA)

5.2.4.3.1 Market size and forecast

5.2.4.4 Colorimetric immunoassay (CI)

5.2.4.4.1 Market size and forecast

5.2.5 Rapid tests

5.2.5.1 Market size and forecast

5.2.6 Enzyme-linked immunospot (ELISPOT)

5.2.6.1 Market size and forecast

5.2.7 Radioimmunoassay (RIA)

5.2.7.1 Market size and forecast

5.2.8 Western blot

5.2.8.1 Market size and forecast

5.3 BLOOD TESTING

5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast

5.4 MOLECULAR DIAGNOSTICS

5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 Polymerize chain reaction (PCR)

5.4.4.1 Market size and forecast

5.4.5 Isothermal nucleic acid technology (INAAT)

5.4.5.1 Market size and forecast

5.4.6 Hybridization

5.4.6.1 Market size and forecast

5.4.7 DNA diagnostics

5.4.7.1 Market size and forecast

5.4.8 Microarray

5.4.8.1 Market size and forecast

5.4.9 Others

5.4.9.1 Market size and forecast

5.5 TISSUE DIAGNOSTICS

5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast

5.6 CLINICAL CHEMISTRY

5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.6.4 Basic metabolic panel

5.6.4.1 Market size and forecast

5.6.5 Liver panel

5.6.5.1 Market size and forecast

5.6.6 Renal profile

5.6.6.1 Market size and forecast

5.6.7 Lipid profile

5.6.7.1 Market size and forecast

5.6.8 Thyroid function panel

5.6.8.1 Market size and forecast

5.6.9 Electrolyte panel

5.6.9.1 Market size and forecast

5.6.10 Speciality chemicals

5.6.10.1 Market size and forecast

5.7 OTHER IVD TECHNIQUES

5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast

CHAPTER 6 IVD MARKET, BY APPLICATION

6.1 INFECTIOUS DISEASES

6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast

6.2 CANCER

6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast

6.3 CARDIAC DISEASES

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast

6.4 IMMUNE SYSTEM DISORDERS

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast

6.5 NEPHROLOGICAL DISEASES

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast

6.6 GASTROINTESTINAL DISEASES

6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast

6.7 OTHERS INDICATIONS

6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast

CHAPTER 7 IVD MARKET BY END USERS

7.1 STANDALONE LABORATORIES

7.1.1 Market size and forecast

7.2 HOSPITALS

7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast

7.3 ACADEMIC AND MEDICAL SCHOOLS

7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast

7.4 POINT OF CARE TESTING

7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast

7.5 OTHERS END-USER

7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast

CHAPTER 8 EUROPE IVD MARKET BY COUNTRY

8.1 Key market trends
8.2 Key growth factors and opportunities
8.3 Market size and forecast
8.4 Germany

8.4.1 Market size and forecast

8.5 France

8.5.1 Market size and forecast

8.6 UK

8.4.6.1 Market size and forecast

8.7 Spain

8.7.1 Market size and forecast

8.8 Italy

8.8.1 Market size and forecast

8.9 Rest of Europe

8.9.1 Market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 THERMO FISHER SCIENTIFIC INC.

9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and development

9.2 ALERE INC.

9.2.1 Company overview
9.2.2 Business performance
9.2.3 Key strategies and developments

9.3 BIOMERIEUX

9.3.1 Company overview
9.3.2 Business performance
9.3.3 Key strategies and developments

9.4 DANAHER CORPORATION

9.4.1 Company overview
9.4.2 Business performance
9.4.3 Key strategies and development

9.5 F. HOFFMANN-LA ROCHE AG

9.5.1 Company overview
9.5.2 Business performance
9.5.3 Key strategies and developments

9.6 BECTON DICKINSON AND COMPANY

9.6.1 Company overview
9.6.2 Business performance
9.6.3 Key strategies and development

9.7 BIO-RAD LABORATORIES

9.7.1 Company overview
9.7.2 Business performance
9.7.3 Key strategies and developments

9.8 BAYER AG

9.8.1 Company overview
9.8.2 Business performance
9.8.3 Key strategies and development

9.9 SYSMEX CORPORATION

9.9.1 Company overview
9.9.2 Business performance
9.9.3 Key strategies and developments

9.10 JOHNSON & JOHNSON

9.10.1 Company overview
9.10.2 Business performance
9.10.3 Key strategies and development

List of Tables

TABLE 1 INCIDENCE OF DISEASES
TABLE 2 EUROPE IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 3 EUROPE IVD REAGENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 4 EUROPE IVD INSTRUMENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 5 EUROPE IVD SOFTWARE & SERVICES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 6 EUROPE IVD MARKET BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 7 EUROPE IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY TYPES, 2016-2023 ($MILLION)
TABLE 8 EUROPE IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY COUNTRY,2016-2023 ($MILLION)
TABLE 9 EUROPE IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET FOR ELISA, BY TYPES, 2016-2023 ($MILLION)
TABLE 10 EUROPE IVD BLOOD TESTING TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11 EUROPE IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 12 EUROPE IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 13 EUROPE IVD TISSUE DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 14 EUROPE IVD CLINICAL CHEMISTRY TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 15 EUROPE OTHER IVD TECHNIQUES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 16 EUROPE IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17 EUROPE IVD INFECTIOUS DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18 EUROPE IVD CANCER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19 EUROPE IVD CARDIAC DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20 EUROPE IVD IMMUNE SYSTEM DISORDER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 21 EUROPE IVD NEPHROLOGICAL DISEASES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 22 EUROPE IVD GASTROINTESTINAL DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23 EUROPE IVD OTHER INDICATION MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24 EUROPE IVD MARKET, BY END USER, 2016-2023, ($MILLION)
TABLE 25 EUROPE IVD STANDALONE LABORATORIES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 26 EUROPE IVD HOSPITALS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27 EUROPE IVD ACADEMIC AND MEDICAL SCHOOLS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 28 EUROPE IVD POINT OF CARE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29 EUROPE IVD OTHER END-USER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 30 EUROPE IVD MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31 EUROPE IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 32 EUROPE IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 33 EUROPE IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34 EUROPE IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 35 GERMANY IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 36 GERMANY IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 37 GERMANY IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38 GERMANY IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 39 FRANCE IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 40 FRANCE IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 41 FRANCE IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 42 FRANCE IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 43 UK IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 44 UK IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 45 UK IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46 UK IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 47 CATEGORIZATION OF IVD DEVICES
TABLE 48 SPAIN IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 49 SPAIN IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 50 SPAIN IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51 SPAIN IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 52 ITALY IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 53 ITALY IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 54 ITALY IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 55 ITALY IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 56 REST OF EUROPE IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 57 REST OF EUROPE IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 58 REST OF EUROPE IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 59 REST OF EUROPE IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 60 THERMO FISHER SCIENTIFIC INC. COMPANY SNAPSHOT
TABLE 61 ALERE INC. COMPANY SNAPSHOT
TABLE 62 BIOMERIEUX COMPANY SNAPSHOT
TABLE 63 DANAHER CORPORATION COMPANY SNAPSHOT
TABLE 64 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 65 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 66 BIO-RAD LABORATORIES, INC. COMAPNY SNAPSHOT
TABLE 67 BAYER AG COMPANY SNAPSHOT
TABLE 68 SYSMEX CORPORATION COMPANY SNAPSHOT
TABLE 69 JOHNSON & JOHNSON PVT LTD. COMPANY SNAPSHOT

List of Figures

FIGURE 1 MARKET SEGMENTATION
FIGURE 2 TOP INVESTMENT POCKETS
FIGURE 3 TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4 TOP WINNING STRATEGIES: NATURE AND TYPE, 2014-2016
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS
FIGURE 6 MARKET SHARE ANALYSIS: IVD MARKET, 2016
FIGURE 7 EUROPE CHEMILUMINESCENCE IMMUNOASSAY (CLISA) MARKET, 2016-2023 ($MILLION)
FIGURE 8 EUROPE FLUORESCENCE IMMUNOASSAY (FIA) MARKET, 2016-2023 ($MILLION)
FIGURE 9 EUROPE COLORIMETRIC IMMUNOASSAY (CI) MARKET, 2016-2023 ($MILLION)
FIGURE 10 EUROPE RAPID TESTS MARKET, 2016-2023 ($MILLION)
FIGURE 11 EUROPE ENZYME-LINKED IMMUNOSPOT (ELISPOT) MARKET, 2016-2023 ($MILLION)
FIGURE 12 EUROPE RADIOIMMUNOASSAY (RIA) MARKET, 2016-2023 ($MILLION)
FIGURE 13 EUROPE WESTERN BLOT TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 14 EUROPE POLYMERIZE CHAIN REACTION PCR MARKET, 2016-2023 ($MILLION)
FIGURE 15 EUROPE ISOTHERMAL NUCLEIC ACID TECHNOLOGY (INAAT) MARKET, 2016-2023 ($MILLION)
FIGURE 16 EUROPE HYBRIDIZATION MARKET, 2016-2023 ($MILLION)
FIGURE 17 EUROPE DNA DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18 EUROPE MICROARRAY MARKET, 2016-2023 ($MILLION)
FIGURE 19 EUROPE OTHER MOLECULAR DIAGNOSTIC TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 20 EUROPE BASIC METABOLIC PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 21 EUROPE LIVER PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 22 EUROPE RENAL PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 23 EUROPE LIPID PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 24 EUROPE THYROID FUNCTION PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 25 EUROPE ELECTROLYTE PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 26 EUROPE SPECIALITY CHEMICALS MARKET, 2016-2023 ($MILLION)
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 30 ALERE INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 31 ALERE INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 32 ALERE INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 33 BIOMERIEUX REVENUE: 2014-2016 ($MILLION)
FIGURE 34 BIOMERIEUX: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 35 BIOMERIEUX: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 36 DANAHER CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 37 DANAHER CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 38 DANAHER CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 39 ROCHE DIAGNOSTICS: REVENUE, 2014-2016 ($MILLION)
FIGURE 40 ROCHE DIAGNOSTICS: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 41 BECTON, DICKINSON AND COMPANY: REVENUE, 2014-2016 ($MILLION)
FIGURE 42 BECTON DICKINSON AND COMPANY: REVENUES BY SEGMENT (%) (2016)
FIGURE 43 BECTON DICKINSON AND COMPANY: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 44 BIO-RAD LABORATORIES: REVENUE, 2014-2016 ($MILLION)
FIGURE 45 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 46 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 47 BAYER AG: REVENUE, 2014-2016 ($MILLION)
FIGURE 48 BAYER AG: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 49 SYSMEX CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 50 SYSMEX CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 51 SYSMEX CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 52 JOHNSON & JOHSNON: REVENUE, 2014 - 2016 ($MILLION)
FIGURE 53 JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 54 JOHNSON & JOHNSON: REVENUE SHARE BY GEOGRAPHY, (%)(2016)

The demand for in vitro diagnostic is on an increase with technological advancements in the diagnostic techniques and awareness about the healthcare industries. The in vitro technology has wide applications, such as diagnosis of infectious diseases, diabetes, oncology/cancer, cardiology diseases, autoimmune diseases, nephrology, drug testing, and HIV/AIDS. Rise in awareness amongst public about healthcare, cost-effective diagnostic solutions, and increase in prevalence of chronic and infectious diseases enhance the growth of the Europe in vitro diagnostics market. The use of automated instruments, point-of-care diagnosis, and increased government expenditure on healthcare in Europe fuel the market. Stringent regulations, policies, and unclear reimbursement rules restrain the market.

The report provides micro level analysis of the factors affecting the market, key market trends, and industry drives and challenges for the better understanding of the market structure. Moreover, assessment of the top investment pockets and winning strategies help channelize their investments in the right directions to garner the market growth.

Online Only ~~$3,456~~ $3,041 Data Pack/Excel ~~$3,840~~ $3,379 Single User License ~~$5,370~~ $4,296 Five User License ~~$6,450~~ $4,838 Enterprise User License ~~$8,995~~ $6,297

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com